Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Eli Lilly & Co. (LLY) Shows Off Its Strong Pipeline

Investors have always known that Eli Lilly and Co (NYSE:LLY) has a strong pipeline, but the community didn’t know the exact number of potential product launches until now. According to a presentation to the investment community that Eli Lilly will make today, the company predicts that it has the potential to launch 20 new products over a ten-year span that began in 2014. Moreover, Eli Lilly believes that it could launch an average of two line extensions or new indications per year for its portfolio of already-approved products during the same time period. Eli Lilly will mainly focus its research and development efforts on five therapeutic areas including four core areas—diabetes, oncology, immunology and neurodegeneration—and one growth area—pain. Anlaysts are pretty bullish on Eli Lilly and Co (NYSE:LLY)’s pipeline and predict the company will grow its earnings per share by an average of 12.44% a year for the next five years. Eli Lilly shares are up by 1.26% today.

Eli Lilly & Co. (NYSE:LLY) was in 57 hedge funds’ portfolios at the end of March. LLY has experienced an increase in hedge fund interest lately. There were 54 hedge funds in our database with LLY positions at the end of the previous quarter. At the end of this article we will also compare LLY to other stocks including Ambev SA (ADR) (NYSE:ABEV), Celgene Corporation (NASDAQ:CELG), and China Petroleum & Chemical Corp (ADR) (NYSE:SNP) to get a better sense of its popularity.

Follow Eli Lilly & Co (NYSE:LLY)
Trade (NYSE:LLY) Now!

We track prominent investors and hedge funds because our research has shown that historically their stock picks delivered superior risk-adjusted returns. This is especially true in the small-cap space. The 15 most popular small-cap stocks among a select group of investors delivered a monthly alpha of 80 basis points between 1999 and 2012 (see the details here).

Of the funds tracked by Insider Monkey, Andreas Halvorsen’s Viking Global has the number one position in Eli Lilly & Co. (NYSE:LLY), worth close to $847.1 million, accounting for 3.7% of its total 13F portfolio. Sitting at the No. 2 spot is D. E. Shaw of D E Shaw, with a $304.3 million position; 0.5% of its 13F portfolio is allocated to the stock. Other peers that are bullish include Hal Mintz’s Sabby Capital, Samuel Isaly’s OrbiMed Advisors, and Jim Simons’ Renaissance Technologies.

On the next page we’ll look at some funds that took up positions in Eli Lilly during Q1, as well as compare the stock to a handful of others with similar market caps.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.